Advances in Cell and Gene Therapy are creating a new revolution in medicine. Early pioneers have advanced our ability to program and modify genes. They have made substantial and dramatic progress, but most of what we can deliver is yet to come.

GeneTether has developed a proprietary method to conjugate, or “tether,” donor DNA templates to CRISPR/Cas9 and other nucleases. We refer to this as our DNA Template-Nuclease-Tethering, or TNT™, Platform.

Our Executive Team

GeneTether’s leadership consists of senior individuals with strong track records in building life sciences companies at all stages of growth.

Roland Boivin, BCom, MBA

Chief Executive Officer & Director

Mr. Boivin brings nearly 25 years of public company leadership experience, with a focus on strategic operations, finance, business development, and general management. Before joining GeneTether as CEO in 2021, he served as CFO at Medexus Pharmaceuticals, Inc. (formerly Pediapharm Inc.), a TSX-listed company focused on innovative rare disease treatment solutions. Among his many accomplishments in that role, Mr. Boivin led the company’s 2013 reverse takeover transaction, helped manage its graduation from the TSXV to the TSX, and played an integral role in its transformative acquisition of two speciality pharma companies. Prior to joining Medexus, Mr. Boivin was CFO at TSXV-listed Golden Hope Mines Limited. Previously, he held a variety of progressive positions at 3M Canada, including running the company’s Consumer Division as Business Unit Manager, and was member of its Executive Committee. Mr. Boivin holds a Bachelor of Commerce in Marketing and Entrepreneurship from McGill University and an Executive MBA from Queen’s University.


Jean Jen, BBA, MPAcc, CPA, CA

Chief Financial Officer

Ms. Jen is a CPA, CA and has over twelve years of finance, accounting experience, working with both private and public companies in the life sciences sector. A highly sought-after consultant for early stage biotechnology companies, Jean held various senior level positions as an independent financial consultant, and most recently held the role of Vice President of Finance at Anandia Laboratories, for which she was recognized as Accountancy Leader of the Year (Top 5 Nominee) by Women in Finance, Canada (2019). From 2013 to 2018, Jean held increasingly senior positions at Arbutus Biopharma Corp. (formerly Tekmira Pharmaceuticals Corp.), a Nasdaq-listed clinical-stage biopharma company with an expertise in liposomal drug delivery and RNA interference, and she helped in with the Company’s growth to $1 billion in market cap. From 2009 to 2013, Ms. Jen worked in KPMG’s advisory and audit practices with a focus on publicly-listed companies. Jean holds a Bachelor of Business Administration degree from Simon Fraser University, as well as Master in Professional Accounting from the University of Saskatchewan.


R. Geoffrey Sargent, PhD

Chief Scientific Officer & Co-Founder

Dr. Sargent has been working in the field of gene editing in mammalian cells since 1987, beginning with his postdoctoral studies at the Imperial Cancer Research Fund (now Cancer Research UK) and Baylor College of Medicine. Dr. Sargent has worked in the Bay Area since 1998, directing academic and biotech company research programs focused on developing high efficiency gene editing technologies for human therapeutics and agricultural applications as well as human pluripotent stem cell applications. He teaches Biochemistry and Stem Cell Biology courses at UC Berkeley Extension and was previously a research scientist at UC San Francisco. Dr. Sargent earned his undergraduate degree in Applied Biology at Georgia Institute of Technology and his PhD in Biochemistry and Biophysics at Oregon State University.


Peter Sampson, BSc, MSc, PhD

Vice President, Research and Development

Peter has over 20 years of drug development experience including discovery chemistry, CMC regulatory affairs and IP portfolio management. Peter joined GeneTether from Scientus Pharma where he served as the Director of Research and Development at Scientus Pharma and led the advancement of their extraction technology through to commercialization. Prior to Scientus Pharma, Peter spent 10 years as a Scientist in the Therapeutics Group at the University Health Network (UHN) where he was involved in discovery research and led the CMC development programs for their PLK4, TTK and HPK1 clinical candidates. Prior to UHN, Peter held various R&D leadership roles of increasing responsibility at Affinium Pharmaceuticals, GlycoDesign Inc. and Albany Molecular Research Inc. Peter holds a BSc in Chemistry from St. Mary’s University and MSc and PhD degrees in Organic Chemistry from the University of Waterloo. He is the co-author of 20 scientific publications and an inventor on over 20 patents.



Daren Graham, BBA, JD

Chairman & Co-Founder 

Mr. Graham has nearly 20 years of experience in the life science industry as a merchant banker, senior operations executive, and corporate finance attorney. He is currently Chief Operating Officer of EGB Ventures. Previously he was a Co-Founder of Osteon Therapeutics, Managing Director of Allele Capital Partners, Executive Director in Tribal Capital Markets’ Equity Capital Life Sciences Division, and Chief Legal Officer and Vice President of Strategic Development at Sancilio Pharmaceuticals Company. Mr. Graham began his career as a corporate finance attorney in the Boston headquarters of Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo PC, representing both private and public life science companies in private and public financings. After receiving a BBA in Finance from Northeastern State University of Oklahoma, Mr. Graham earned his Juris Doctorate from Boston College Law School. He is a member of the Massachusetts Bar and holds FINRA Series 7, 63 and 79 licenses.

William J. Garner, MD, MPH

Director & Co-Founder

Dr. Garner is a physician, investor and entrepreneur who has founded and co-founded numerous life science companies, including Race Oncology, Tryp Therapeutics, and Isla Pharmaceuticals, among others. In addition to serving as Founder and Managing Director of EGB Ventures, Dr. Garner has served in management roles and on the boards of a number of EGB Ventures portfolio companies. Prior to EGB, Dr. Garner held positions in the medical affairs division of Hoffmann LaRoche – Oncology and at a merchant banking firm in New York City. Dr. Garner earned his MD from New York Medical College and a Masters of Public Health from the Harvard T.H. Chan School of Public Health. He trained in the Anatomic Pathology residency program at Columbia-Presbyterian and is currently a licensed physician in the State of New York.


André Fraga

Director

André Fraga is the founding partner of Aurea Holdings with over 20 years of experience in M&A, Strategy and Business Development, first in the Petrochemical sector and later in the Renewable Energy sectors, representing over 6 gigawatts in Europe, South America and Asia. In addition, he is an active investor in Biotech companies, participating in early-stages fund raises as well as finding co-investors and/or potential partners for his investment companies. Currently he is Chief Executive officer of Renovatio Group and serves as a NED in GeneTether and OnOn Holdings. Mr Fraga obtained his undergraduate in Business Studies from Universidade Católica Portuguesa, holds an International MBA from Instituto de Empresa (IE) and has undertaken an Executive Education Program at Harvard Business School .